April 17th 2025
The interchangeability designation for Yuflyma, a biosimilar to Humira, may help to improve patient access and reduce costs.
Keeping Counterfeit Goods Out of the Supply Chain
August 16th 2024In the final part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, comments on other ways to limit ‘bad actors’ attempts to sneak counterfeit drugs into the supply chain, aside from the DSCSA.
A Breadcrumb of Serialized Data
August 8th 2024In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, discusses the state of affairs surrounding the Drug Supply Chain Security Act, along with opportunities for improvement.
Effects of the Federal Trade Commission's Repeal of Non-Compete Agreements on the Pharma Industry
May 21st 2024In an interview with Pharma Commerce Associate Editor Don Tracy, Ron Lanton, Partner, Lanton Law offers his thoughts on the recent Federal Trade Commission (FTC) repeal of non-compete agreements, and how it could effect the pharma industry.